S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NASDAQ:SPRO

Spero Therapeutics (SPRO) Stock Forecast, Price & News

$1.23
-0.01 (-0.81%)
(As of 09/20/2023 ET)
Compare
Today's Range
$1.20
$1.26
50-Day Range
$1.23
$1.63
52-Week Range
$0.81
$3.18
Volume
394,148 shs
Average Volume
395,746 shs
Market Capitalization
$64.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Spero Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
509.8% Upside
$7.50 Price Target
Short Interest
Healthy
2.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
-0.07mentions of Spero Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$69,298 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.51) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

303rd out of 961 stocks

Pharmaceutical Preparations Industry

137th out of 454 stocks


SPRO stock logo

About Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

SPRO Price History

SPRO Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
4 Analysts Have This to Say About Spero Therapeutics
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Q2 2023 Spero Therapeutics Inc Earnings Call
Spero Therapeutics earnings: here's what Wall Street expects
Spero Therapeutics (SPRO) Receives a Buy from H.C. Wainwright
SPRO - Spero Therapeutics, Inc.
See More Headlines
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Company Calendar

Last Earnings
8/10/2023
Today
9/20/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
35
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+509.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-46,420,000.00
Pretax Margin
-18.59%

Debt

Sales & Book Value

Annual Sales
$53.51 million
Book Value
$1.45 per share

Miscellaneous

Free Float
50,497,000
Market Cap
$64.85 million
Optionable
Optionable
Beta
0.89

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Ankit Mahadevia M.D. (Age 42)
    MBA, Co-Founder & Chairman
    Comp: $1.24M
  • Mr. Satyavrat Shukla C.F.A. (Age 50)
    Pres, CEO & Director
    Comp: $823.27k
  • Ms. Tamara Lynn Joseph L.L.M. (Age 60)
    Chief Legal Officer
    Comp: $775.55k
  • Mr. Stephen J. Dipalma M.B.A.
    Interim CFO & Treasurer
  • Mr. Timothy Keutzer (Age 55)
    Chief Operating Officer
  • Ted Jenkins
    VP & Head of Investor Relations
  • Mr. James P. Brady
    Chief Human Resource Officer
  • Dr. Kamal Hamed M.B.A. (Age 62)
    M.D., M.P.H., Chief Medical Officer













SPRO Stock - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares.
View SPRO analyst ratings
or view top-rated stocks.

What is Spero Therapeutics' stock price forecast for 2023?

3 brokerages have issued 1 year price objectives for Spero Therapeutics' stock. Their SPRO share price forecasts range from $7.00 to $8.00. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 509.8% from the stock's current price.
View analysts price targets for SPRO
or view top-rated stocks among Wall Street analysts.

How have SPRO shares performed in 2023?

Spero Therapeutics' stock was trading at $1.73 on January 1st, 2023. Since then, SPRO shares have decreased by 28.9% and is now trading at $1.23.
View the best growth stocks for 2023 here
.

When is Spero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our SPRO earnings forecast
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.06. The company had revenue of $2.72 million for the quarter, compared to the consensus estimate of $2.20 million. Spero Therapeutics had a negative net margin of 18.59% and a negative trailing twelve-month return on equity of 17.69%.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Anson Funds Management LP (6.54%), Atlas Venture Life Science Advisors LLC (1.93%), Renaissance Technologies LLC (1.13%), BlackRock Inc. (1.00%), Geode Capital Management LLC (0.74%) and AWM Investment Company Inc. (0.73%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin, Kamal Hamed, Sath Shukla and Timothy Keutzer.
View institutional ownership trends
.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $1.23.

How much money does Spero Therapeutics make?

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $64.85 million and generates $53.51 million in revenue each year. The company earns $-46,420,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.

This page (NASDAQ:SPRO) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -